Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 4/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.35 |
| ▸ | PTGIR | P43119 | 2/20 | 0.35 |
| ▸ | MIF | P14174 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14431637 | 0.89 | PPARG (0.38) | MEN1KMT2APTGIRPTGDR | |
| SCHEMBL5213182 | 0.77 | PTGIR (0.42) | SIGMAR1PTGIRPTGDR | |
| SCHEMBL5407704 | 0.74 | PPARG (0.43) | PTPN1 | |
| SCHEMBL28851015 | 0.74 | PSMB5 (0.54) | TRPM8MEN1KMT2APSMB5MIF | |
| SCHEMBL28851016 | 0.74 | PSMB5 (0.54) | TRPM8MEN1KMT2APSMB5MIF | |
| SCHEMBL5414067 | 0.73 | CA12 (0.40) | HPGDPTGIRTDP1PTGDR | |
| SCHEMBL27600882 | 0.69 | PSMB5 (0.41) | LMNAHPGDTRPM8MEN1KMT2A | |
| SCHEMBL16672540 | 0.69 | ALDH1A1 (0.49) | TRPM8MEN1KMT2APSMB5TDP1 | |
| SCHEMBL7900470 | 0.69 | ALDH1A1 (0.49) | TRPM8MEN1KMT2APSMB5TDP1 | |
| SCHEMBL16559554 | 0.69 | ALDH1A1 (0.49) | TRPM8MEN1KMT2APSMB5TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1354879-B1 | DIHYDRONAPHTHALENE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2007-08-15 | — | — | EP | disclosed |
| EP-1354879-B1 | DIHYDRONAPHTHALENE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2007-08-15 | — | — | EP | disclosed |
| US-7220864-B2 | Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-7220864-B2 | Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-7220864-B2 | Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-20060287304-A1 | Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2006-12-21 | — | — | US | disclosed |
| EP-1726586-A1 | Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
| US-20040138213-A1 | Dihydronaphthalene derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1354879-A1 | DIHYDRONAPHTHALENE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287304-A1 | Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient | SREBF1, NR1H2, NR1H3 | NLRP3 1311/4885SIGMAR1 1017/4885LMNA 1443/4885 |
| US-20040138213-A1 | Dihydronaphthalene derivative compounds and drugs containing these compounds as the active ingredient | SREBF1, NR1H2, NR1H3 | NLRP3 1490/4885SIGMAR1 542/4885LMNA 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.